Sustainable Development Capital LLP’s (SDCL) global energy transition fund has made a €100m commitment to a new partnership with CarbonAMS to develop Irish biomethane facilities.
SDCL’s Global Energy Transition Fund (GETF) will provide capital investment needed to deliver the 40GWh pa facility in Duleek, County Meath, which will produce and sell renewable energy to Alexion, which is part of pharmaceutical firm AstraZeneca.
SDCL and CarbonAMS will both become shareholders in the project, with CarbonAMS also managing the construction and operational phases of the Duleek facility.
The Duleek facility marks the first of 10 planned anaerobic digestion sites for Carbon AMS in the Republic of Ireland which will entail a planned spend of €200m in the coming years.
The partnership also involves SDCL funding CarbonAMS projects on reaching ‘ready-to-build’ stage, creating a pipeline of high-quality biomethane facilities in Ireland.
Jonathan Maxwell, founder and CEO of SDCL, said: “Our investment in the Duleek Project reflects SDCL’s commitment to accelerating the decarbonisation of energy-intensive industries through practical, scalable clean-energy solutions.
“This project will deliver renewable biomethane directly to one of Ireland’s leading pharmaceutical companies, demonstrating how collaboration between investors, developers and corporates can drive meaningful progress toward net zero.”
Richard Kennedy, founder and CEO of Carbon AMS, said: “We are thrilled to partner with SDCL and Alexion, AstraZeneca Rare Disease on our shared vision for a sustainable future. This agreement is a game-changer for the Irish agri-biomethane sector, demonstrating the significant potential for indigenous, renewable gas production.
“The Duleek facility will not only provide Alexion with a reliable source of clean heat but also support local agriculture and contribute to Ireland’s energy independence.”
To read the latest IPE Real Assets magazine click here.
